Add to ORKGBackgroundThe validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™) is a standardized severity assessment for use in clinical trials and registries for atopic dermatitis (AD).ObjectivesTo investigate the reliability, validity, responsiveness and within-patient meaningful change of the vIGA-AD.MethodsData were analysed from adult patients with moderate-to-severe AD in the BREEZE-AD1 (N = 624 patients; NCT03334396), BREEZE-AD2 (N = 615; NCT03334422) and BREEZE-AD5 (N = 440; NCT03435081) phase III baricitinib clinical studies.ResultsAcross studies, test-retest reliability for stable patients showed moderate-to-good agreement [range of Kappa values for Patient Global Impression of Severity-Atopic Dermatitis (PGI-S-AD), 0·516...
Well-designed clinical trials are a fundamental aspect of evidence-based medicine. Such trials are d...
The use of nonstandardized and inadequately validated outcome measures in atopic eczema trials is a ...
The use of nonstandardized and inadequately validated outcome measures in atopic eczema trials is a ...
BACKGROUND: An Investigator Global Assessment (IGA) is recommended by health agencies for drug regis...
Introduction: Atopic dermatitis (AD) is the most common chronic inflammatory skin disease in the Uni...
The lack of core outcome sets for atopic eczema (AE) is a major obstacle for advancing evidence-base...
The lack of core outcome sets for atopic eczema (AE) is a major obstacle for advancing evidence-base...
The lack of core outcome sets for atopic eczema (AE) is a major obstacle for advancing evidence-base...
INTRODUCTION: Assessing treatment response is key to determining treatment value in atopic dermatiti...
© 2019 British Association of Dermatologists Background: Structured patient-reported outcomes of ato...
Abstract Introduction Assessing treatment response is key to determining treatment value in atopic d...
Summary Background There are multiple severity outcome measures for atopic dermatitis (AD). There is...
BACKGROUND: Valid and reliable outcome measurements are a prerequisite for evidence-based practice. ...
BackgroundSymptoms have been identified as a core outcome domain for atopic eczema (AE) trials. Vari...
BACKGROUND: A number of disease-severity and quality-of-life (QoL) instruments have emerged in atopi...
Well-designed clinical trials are a fundamental aspect of evidence-based medicine. Such trials are d...
The use of nonstandardized and inadequately validated outcome measures in atopic eczema trials is a ...
The use of nonstandardized and inadequately validated outcome measures in atopic eczema trials is a ...
BACKGROUND: An Investigator Global Assessment (IGA) is recommended by health agencies for drug regis...
Introduction: Atopic dermatitis (AD) is the most common chronic inflammatory skin disease in the Uni...
The lack of core outcome sets for atopic eczema (AE) is a major obstacle for advancing evidence-base...
The lack of core outcome sets for atopic eczema (AE) is a major obstacle for advancing evidence-base...
The lack of core outcome sets for atopic eczema (AE) is a major obstacle for advancing evidence-base...
INTRODUCTION: Assessing treatment response is key to determining treatment value in atopic dermatiti...
© 2019 British Association of Dermatologists Background: Structured patient-reported outcomes of ato...
Abstract Introduction Assessing treatment response is key to determining treatment value in atopic d...
Summary Background There are multiple severity outcome measures for atopic dermatitis (AD). There is...
BACKGROUND: Valid and reliable outcome measurements are a prerequisite for evidence-based practice. ...
BackgroundSymptoms have been identified as a core outcome domain for atopic eczema (AE) trials. Vari...
BACKGROUND: A number of disease-severity and quality-of-life (QoL) instruments have emerged in atopi...
Well-designed clinical trials are a fundamental aspect of evidence-based medicine. Such trials are d...
The use of nonstandardized and inadequately validated outcome measures in atopic eczema trials is a ...
The use of nonstandardized and inadequately validated outcome measures in atopic eczema trials is a ...